H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akebia to $5 from $3.75 and keeps a Buy rating on the shares post the Q3 report. The analyst says Vadadustat is approved in 36 countries to date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKBA:
- Biotech Alert: Searches spiking for these stocks today
- Akebia reports Q3 EPS (8c) vs. (29c) last year
- Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- AKBA Earnings this Week: How Will it Perform?
- Akebia announces FDA accepted resubmission of NDA for vadadustat
